These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 9504174

  • 1. Physiological versus pharmacological decongestion of the nose in healthy human subjects.
    Flanagan P, Eccles R.
    Acta Otolaryngol; 1998 Jan; 118(1):110-3. PubMed ID: 9504174
    [Abstract] [Full Text] [Related]

  • 2. Nasal airflow resistance: a survey of 2500 assessments.
    Cole P.
    Am J Rhinol; 1997 Jan; 11(6):415-20. PubMed ID: 9438053
    [Abstract] [Full Text] [Related]

  • 3. Nasal airflow asymmetry and the effects of a topical nasal decongestant.
    Williams RG, Eccles R.
    Rhinology; 1992 Dec; 30(4):277-82. PubMed ID: 1281924
    [Abstract] [Full Text] [Related]

  • 4. [Rhinomanometric tests of the effect of nasivinettes in normal subjects (author's transl)].
    Ey W, Skevas A.
    Laryngol Rhinol Otol (Stuttg); 1974 Mar; 53(5):352-7. PubMed ID: 4136431
    [No Abstract] [Full Text] [Related]

  • 5. Use of pharmacologic decongestion in the generation of rhinomanometric norms for the nasal airway.
    Jessen M, Malm L.
    Am J Otolaryngol; 1988 Mar; 9(6):336-40. PubMed ID: 2465702
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of decongestant activity of alpha 2-adrenoceptor agonists.
    Corboz MR, Rivelli MA, Mingo GG, McLeod RL, Varty L, Jia Y, Hey JA.
    Pulm Pharmacol Ther; 2008 Mar; 21(3):449-54. PubMed ID: 17869148
    [Abstract] [Full Text] [Related]

  • 7. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion.
    Morris S, Eccles R, Martez SJ, Riker DK, Witek TJ.
    Am J Rhinol; 1997 Mar; 11(2):109-15. PubMed ID: 9129752
    [Abstract] [Full Text] [Related]

  • 8. Comparative evaluation of nasal blood flow and airflow in the decongestant response to oxymetazoline.
    Vaidyanathan S, Williamson P, Lipworth B.
    Ann Allergy Asthma Immunol; 2012 Feb; 108(2):77-80. PubMed ID: 22289724
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effects of oxymetazoline on lysozyme secretion from the human nasal mucosa.
    Browning S, Housley D, Richards R, Eccles R.
    Acta Otolaryngol; 1997 Nov; 117(6):851-5. PubMed ID: 9442826
    [Abstract] [Full Text] [Related]

  • 13. Decongestion effect and rebound swelling of the nasal mucosa during 4-week use of oxymetazoline.
    Graf P, Juto JE.
    ORL J Otorhinolaryngol Relat Spec; 1994 Nov; 56(3):157-60. PubMed ID: 7515487
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nasal airway resistance after decongestion with a nasal spray or a bellows device.
    Jessen M, Ivarsson A, Malm L.
    Rhinology; 1996 Mar; 34(1):28-31. PubMed ID: 8739865
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vascular effects of topical oxymetazoline on human nasal mucosa.
    Bende M, Löth S.
    J Laryngol Otol; 1986 Mar; 100(3):285-8. PubMed ID: 3950497
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.